ILK and central nervous system cancer: ILK1 was significantly more expressed in the subset of patients with early recurrence in all three types of glioma (Figures 6E and 6F; astrocytomas: NR 0.47±0.12 R 2.51±0.9; oligodendrogliomas NR 0.6±0.13 R 1.2±0.2; GBMs NR 0.4±0.07 R 0.9±0.15).